Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

HCV Clinical Trial

Official title:

Pharmacokinetics, Safety, Efficacy and Acceptability Study of Daclatasvir/Sofosbuvir in Children Weighing 14-35 Kilograms With Chronic Hepatitis C Virus Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05854511
• Other study ID #: FMASU P04a / 2022
• Status: Recruiting
• Phase: Phase 3
• Start date: June 5, 2022
• Est. completion date: April 13, 2024

Study information

• Verified date: May 2023
• Source: Ain Shams University
• Contact: Manal H. El-Sayed, MD
• Phone: 002-01227461120
• Email: manalhelsayed[@]yahoo.co.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection.

Description:

This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve, children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection. All enrolled patients will receive daclatasvir 30 mg orally once daily plus sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks. Patients will be followed closely for disease progression and any hypersensitivity or adverse reactions due to therapy. Laboratory values to be monitored at baseline are serum creatinine, bilirubin, Aspartate transaminase (AST), Alanine transaminase (ALT), viral load (VL). patients will be recruited in each of two weight bands (14 to < 17 kg and 17 to 35 kg). The study is mainly powered for non-compartmental pharmacokinetics determination of DCV, SOF and GS-331007. Patient recruitment will be done at Ain Shams university hospitals, Egypt. The study be will conducted after approval by the corresponding research ethical committee and obtaining an informed consent from the parents or the legal guardians, and -whenever applicable- an assent from the patients. Total number of visits is 7 for patients who will complete the study, a screening visits, at the first day of therapy, at weeks 1, 4, 8, 12 and 24 after starting daclatasvir plus sofosbuvir. Patients who will complete their treatment schedule will come after 12 weeks for assessment of SVR. Duration of follow up will be 6 months from treatment initiation in addition to screening period (2-4 weeks).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: April 13, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years and older

Eligibility

Inclusion Criteria:

• Children more than 3 years of age and weighing 14-35kg
• Infected with HCV genotypes 1-6
• Treatment Naïve HCV-infected children
• Signing a written consent form by the parent or the legal guardian, and -whenever applicable- an assent by the patient
• Screening laboratory values within predefined thresholds:

1. Absolute neutrophil count = 1,500/mm3

2. Platelets > 50,000 cells/mm3

3. Albumin > 3.5 mg/dL

4. Prothrombin Time PT < 4 sec above control Or International Normalized Ratio INR <1.7 3

5. Random blood glucose level within normal range (> 70 mg/dL and < 200 mg/dL)

6. Serum creatinine < 1.5 mg/dL

Exclusion Criteria:

• Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus
• Clinical hepatic decompensation, i.e., Child-Turcotte-Pugh CTP class B or C (i.e., jaundice, ascites, encephalopathy, or variceal hemorrhage)
• Renal dysfunction, i.e., eGFR < 60 mL/min/1.73 m2 or on regular dialysis as calculated by Schwartz Formula
• Alfa-fetoprotein level > 50 ng/mL
• Chronic liver disease due to a cause other than HCV or Known hypersensitivity to daclatasvir or sofosbuvir.
• History of gastrointestinal disease or gastrointestinal surgical procedure that would impair the absorption of the study drug
• Blood/blood product transfusion within 4 weeks prior to study.
• Systemic corticosteroid administration for more than 2 weeks starting from two weeks before study inclusion and till the end of treatment period (pulmonary/nasal administration is permitted).
• Psychiatric hospitalization, suicide attempt or disability resulting from psychiatric illness within the prior 5 years.
• Ongoing treatment with any medications interacting with daclatasvir/sofosbuvir.

Related Conditions & MeSH terms

• HCV

Intervention

Drug:
• Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.

Locations

Country	Name	City	State
Egypt	Faculty of Medicine, Ain-Shams University Research Institute-Clinical Research Centre (MASRI-CRC)	Cairo

Sponsors (2)

Lead Sponsor	Collaborator
Ain Shams University	Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma concentration of Daclatasvir	The plasma concentration of Daclatasvir on day 8 will be used to derive the Pharmacokinetic parameters using the Non-Compartmental analysis (NCA)	one week
Primary	Plasma concentration of Sofosbuvir	The plasma concentration of Daclatasvir on day 8 will be used to derive the Pharmacokinetic parameters using the Non-Compartmental analysis (NCA)	one week
Secondary	Efficacy of Daclatasvir 30 MG oral tablets and Sofosbuvir 200 MG oral tablets once daily for 12 weeks	Efficacy will be assessed via sustained virologic response at 12 weeks after the 12 weeks treatment completion (SVR12)	24 weeks
Secondary	Safety of Daclatasvir 30 MG oral tablets and Sofosbuvir 200 MG oral tablets once daily for 12 weeks	Safety o will be assessed by recording any adverse event occurs in treatment period and 2-4 weeks after the last visit (after week 24)	24 weeks